Get started
Author

Anja Pomowski

Observed names: A. Pomowski, Pomowski, Anja
Observed institutions: University of Freiburg, University of Cambridge, Stevenage Bioscience Catalyst, Antikor (United Kingdom), Wellcome Trust, Medical Research Council
ORCID: 0009-0005-4120-2113
Observed ORCID: 0009-0005-4120-2113
OpenAlex ID: A5085951351
N2O binding at a [4Cu:2S] copper–sulphur cluster in nitrous oxide reductase
2011 · Anja Pomowski, Walter G. Zumft, et al. · Nature · 224
Structure and Mechanism of Cysteine Peptidase Gingipain K (Kgp), a Major Virulence Factor of Porphyromonas gingivalis in Periodontitis
2014 · Iñaki de Diego, Florian Veillard, et al. · Journal of Biological Chemistry · 112
PDF
Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?
2018 · Mahendra Deonarain, Gokhan Yahioglu, et al. · Antibodies · 94
PDF
Nature’s way of handling a greenhouse gas: the copper-sulfur cluster of purple nitrous oxide reductase
2012 · Anja Wüst, Lisa Schneider, et al. · Biological Chemistry · 48
PDF
Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1
2019 · Katherine A. Vousden, Tomas Lundqvist, et al. · Scientific Reports · 33
PDF
Homology model of human prothrombinase based on the crystal structure of Pseutarin C
2014 · Anja Pomowski, Fatma Isik Ustok, et al. · Biological Chemistry · 19
No Laughing Matter: The Unmaking of the Greenhouse Gas Dinitrogen Monoxide by Nitrous Oxide Reductase
2014 · Lisa K. Schneider, Anja Wüst, et al. · Metal ions in life sciences · 18
Crystallization of purple nitrous oxide reductase fromPseudomonas stutzeri
2010 · Anja Pomowski, Walter G. Zumft, et al. · Acta Crystallographica Section F Structural Biology and Crystallization Communications · 18
PDF
Structural insights unravel the zymogenic mechanism of the virulence factor gingipain K from Porphyromonas gingivalis, a causative agent of gum disease from the human oral microbiome
2017 · Anja Pomowski, Isabel Usón, et al. · Journal of Biological Chemistry · 16
Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al. · Molecular Cancer Therapeutics · 5
Revisiting the metal sites of nitrous oxide reductase in a low-dose structure from Marinobacter nauticus
2024 · Anja Pomowski, Simone Dell’Acqua, et al. · JBIC Journal of Biological Inorganic Chemistry · 5
PDF
Abstract 909: Antibody fragment drug-conjugates (FDCs)-application of ANT-043 and ANT-045 in solid tumors
2021 · Mahendra P. Deonarain, Gokhan Yahioglu, et al. · Cancer Research · 3
Abstract 2901: Gastric cancer antibody fragment drug-conjugates (FDCs): From concept to clinical development
2020 · Mahendra P. Deonarain, Gokhan Yahioglu, et al. · Cancer Research · 2
Pseudomonas stutzeri nitrous oxide reductase, P1 crystal form with substrate
2011 · A. Pomowski, W.G. Zumft, et al. · Worldwide Protein Data Bank · 1
Abstract 4399: ANT045: A novel format, antibody fragment drug-conjugate (FDC) product for challenging cMET-expressing solid tumors
2026 · Mahendra Deonarain, Bryan Edwards, et al. · Cancer Research
Abstract 2408: ADCs in cancer treatment: SPR-driven insights into discovery and characterization.
2026 · Soraya Diez-Posada, Cynthia Shuman, et al. · Cancer Research
Supplementary Figure 4 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Data from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Figure 1 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Figure 9 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Table 2 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Table 4 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Table 1 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Figure 2 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Figure 3 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Works count: 40
Citation count: 598
H-index: 9
I10-index: 9
Year
Topic
Type